Table 1.

Studies of Vaccine Effectiveness in LTC Users

Study (Country)	Vaccine Studied	Study Overview	VE Estimates
Britton et al³ (United States)	BioNTech/Pfizer	Outbreak report after breakthrough infections; 2 facilities (463 residents, 81% had at least 1 dose)	VE against infection after first dose: 63% (95% CI 33-79).
Cavanaugh et al⁴ (United States)	BioNTech/Pfizer	Outbreak report after breakthrough infections; 1 facility (83 residents, 90% had 2 doses)	VE among fully vaccinated residents (>14 d after second dose): against infection 66% (95% CI 41-81); against symptomatic illness 87% (95% CI 66-95); against death 94% (95% CI 45-99)
Rask-Moustsen Helms et al¹ (Denmark)	BioNTech/Pfizer	Cohort study; 39,040 residents at LTC facilities (95% vaccinated with at least 1 dose)	No protective effect against infection after first dose VE against infection after second dose: 52% (95% CI 27-69) after 0-7 d, and 64% (95% CI 14-84) beyond 7 d
Shrotri et al² (England)	Oxford/AstraZeneca and Pfizer/BioNTech	Cohort study; 10,412 residents at LTC facilities (88% vaccinated with at least 1 dose)	VE against infection after first dose: 56% (95% CI 19-76) at 28-34 d; 62% (95% CI 23-81) at 35-48 d

CI, confidence interval; VE, vaccine effectiveness.